Cryo-Cell International Inc

Cryo-Cell operates with a negative equity position of $10.74 million and a debt-to-equity ratio of -0.79, indicating a capital structure heavily reliant on debt financing. The company maintains $469,200 in cash and equivalents, but its operating cash flow of $1.42 million is insufficient to cover its long-term debt of $8.53 million, resulting in a liquidity risk rating of medium. The current ratio of 0.52 suggests the company may struggle to meet short-term obligations with its current assets. Profitability metrics show mixed results. The company reported a net income of $655,790 on $8.04 million in revenue, translating to a net margin of 8.15%. However, its return on equity is negative at -6.11%, reflecting the impact of its negative equity position. Return on assets is positive at 1.05%, but this is below the typical performance of industry peers, which often exceed 5% in this sector. Cryo-Cell's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. This lack of diversification increases exposure to market-specific risks, particularly in the cord blood and tissue banking niche. The company's growth trajectory is constrained by its financial position. With a negative free cash flow of $983,920 and capital expenditures of $2.21 million, Cryo-Cell is investing in operations but not generating sufficient cash to sustain these investments. Analysts have assigned a "Hold" rating, with no strong buy or buy recommendations, and the last actual EPS of -$0.30 contrasts sharply with the mean EPS estimate of $0.08, indicating a potential earnings gap. The risk assessment highlights liquidity concerns, with net cash being negative after subtracting total debt. While dilution risk is currently rated as low, the company's negative equity and reliance on debt financing could increase dilution pressure if it needs to raise additional capital. No recent events or filings have been disclosed that would significantly alter the company's risk profile. Cryo-Cell's recent financial performance and analyst sentiment suggest a cautious outlook. The company's market price of $3.68 and a price-to-earnings ratio of 45.2 indicate a premium valuation relative to earnings, which may not be sustainable given its current profitability and cash flow challenges.